Dublin, Jan. 12, 2017 -- Research and Markets has announced the addition of the "Hospital Acquired Infections Forecast in 15 Major Markets 2017-2027" report to their offering.
Hospital acquired infections (HAI), or nosocomial infections - infections acquired by patients or staff during in-patient care (hospital admission). This is the point or annual prevalence of HAI (or HCAI), equivalent to a number of cases of an infection per year. HAI can be caused by any pathogen, including bacteria, viruses and fungi.
This report provides the current incident population for Hospital Acquired Infections across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Netherlands, Sweden, Norway, Denmark, Finland, Poland, Romania, Czech Republic and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Hospital Acquired Infections have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line Incidence for Hospital Acquired Infections
10. HAI by major site of infection
11. HAI by main pathogen
12. Treatment of HAIs
13. Abbreviations used in the report
14. Patient-Based Offering
15. Online Pricing Data and Platforms
16. References
17. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/5scl45/hospital_acquired
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
First Western Ship Transits Strait of Hormuz Since Iran War Began
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 



